Business Context and Reporting Period
Company: PureSnax International, Inc. (Note: Input metadata referenced "Iqstel Inc," but the filing text identifies the registrant as PureSnax International, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2017
Business Overview: The Company is a wellness brand focused on developing, sourcing, and distributing healthy snacks and foods, including sugar-free, vegan, and Xylitol-sweetened products. As of March 8, 2017, the Company exited a previous license agreement and is developing its own proprietary brand. The Company currently has no full-time employees and outsources production and fulfillment.
Key Financial Metrics
| Metric | Year Ended June 30, 2017 | Year Ended June 30, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(263,691) | $(245,047) |
| Total Expenses | $114,314 | $174,873 |
| Other Income/(Expense) | $(149,377) | $(70,174) |
| Cash and Cash Equivalents (End of Period) | $15,701 | $23,790 |
| Working Capital Deficit | $(208,979) | $(173,557) |
| Accumulated Deficit | $(573,368) | $(309,677) |
| Convertible Notes Payable (Net) | $35,574 | $32,490 |
| Derivative Liability | $98,041 | $112,243 |
| Common Shares Outstanding | 441,338,708 | 100,235,384 |
Material Changes vs. Prior Period
- Revenue: The Company generated no revenue in either period.
- Net Loss: Net loss increased by approximately 7.6% to $(263,691) from $(245,047). This increase was primarily driven by higher interest and derivative expenses.
- Expenses: Total operating expenses decreased by $60,559 (34.6%) due to significant reductions in marketing expenses (from $23,322 to $190) and other expenses. However, the Company recorded a $12,187 loss on inventory obsolescence in 2017, which was not present in 2016.
- Non-Operating Items: Interest expense surged to $(120,346) from $(25,993), largely due to the amortization of debt discounts ($112,911). Derivative expenses increased to $(43,234) from $(13,401).
- Liquidity: Cash reserves declined by $8,089. The Company utilized $69,944 in operating cash flows but received $61,855 from financing activities (primarily loans).
- Capital Structure: Common shares outstanding increased significantly (from ~100 million to ~441 million) due to the conversion of convertible notes and warrants into common stock.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that the Company's continuing operating losses and lack of revenue raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might be necessary if the Company cannot continue operations.
- Financing Needs: Management estimates a need for an additional $50,000 to $100,000 to purchase raw materials, packaging, and fund introductory marketing. Commercial scale product development costs are estimated to exceed $100,000. The Company intends to secure funding through the sale of common stock or loans.
- Operational Status: The Company has no full-time employees and relies on part-time consultants. It has exited a previous licensing agreement and is in the conceptualization phase for new products.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2017. Material weaknesses were identified, including a lack of an audit committee, insufficient skilled personnel, and improper segregation of duties.
- Market Risk: The Company is subject to risks associated with the health food industry, regulatory compliance (FDA), and the volatility of its stock price which impacts the valuation of derivative liabilities.
Investor Verification Checklist
- Capital Adequacy: Verify if the Company has secured the estimated $50,000–$100,000 in additional financing required to proceed with commercial production.
- Revenue Generation: Confirm if the Company has generated any revenue from its new proprietary brand since exiting the previous license agreement in March 2017.
- Debt Obligations: Review the terms of the outstanding convertible notes ($35,574 net) and the significant derivative liability ($98,041) to understand potential dilution or cash settlement risks.
- Internal Controls: Assess the Company's progress in remedying the identified material weaknesses in internal controls over financial reporting.
- Share Dilution: Monitor the rapid increase in share count (from 100M to 441M in one year) and the impact of further conversions of notes and warrants on existing shareholders.